

BIBLIOGRAFÍA

BIBLIOGRAFIA :

- 1- Derek Raghavan, Howard I. Scher, Steven A. "Epidemiology of testicular cancer. En: Principles and Practice of Genitourinary Oncology". Leibel, and Paul H. Lange. Lippincott-Raven Publishers. Cap 6, 643-652, 1997.
- 2- Germá Lluch JR.: En: "Tumores germinales de testículo": Ed. Doyma, Cap 1, p-1-2. 1991.
- 3- Bokemeyer C, Schmoll HJ, Schoffski P et al: "Bilateral testicular tumours; prevalence and clinical implications". Eur J Cancer 29A:874-876, 1993.
- 4- Romero F: "Registro de Tumores de la VIII Sección de la AEU". Libro de Abstracts LIX Congreso Nacional de Urología 95-101, 1994.
- 5- Pakin DM, Muir CS, Whelan SL et al, eds: "Cancer incidence in five continents". Lyon, France International Agency for research on Cancer 6. 1992.
- 6- Coleman MP, Esteve J, Damiechi P et al. : Testis, m: "Trends in cancer incidence and mortality". Lyon, France: International Agency for Research on Cancer 529-4, 1993.
- 7- Senturia ID.: "The epidemiology of testicular cancer". Br J Urol 60:285-291, 1987.

- ⁸⁻ Schottenfeld D, Warshauer: *Testis*. In Schottenfeld and Fraumeni (eds). “Cancer Epidemiology and prevention”. W.B. saunders Company 56:947-957, 1982.
- ⁹⁻ Brown LM, Pottern LM, Hoover RN et al. “Testicular cancer in the United States: Trends in incidence and mortality”. *Int J Epidem* 15(2):164-170. 1986.
- ¹⁰⁻ Moller H. “Clues to aetiology in testicular germ cell tumours from descriptive epidemiology”. *Eur Urol* ;23(1):8-13, 1993.
- ¹¹⁻ Registre Poblacional de Cáncer de Tarragona (Departament de Sanitat i Seguretat Social. Generalitat de Catalunya). (www.netcat.com).
- ¹²⁻ Spitz MR. Sider JG, Pollack ES et al: “Incidence and descriptive features of testicular cancer among United States white, blacks and Hispanics”. 1973-1982. *Cancer* 58: 1785-90, 1986.
- ¹³⁻ Stone JM, Cruickshank DG, Sandeman TF et al.: “Laterality. Maledescents, trauma and other clinical factors in the epidemiology of testis cancer in Victoria. Australia”. *Br J Cancer* 64(1):132-8, 1991.
- ¹⁴⁻ Lincoln GA: “Pituitary control of testicular activity”. *Br Med Bull*. 35:167-172, 1979.
- ¹⁵⁻ Morrison AS: “Cryptorchidism, hernia and cancer of the testis”. *JNCI* 56:731-33, 1976.

- ¹⁶⁻ Mostofi FK: "Testicular tumours: Epidemiology, etiology and pathologic features". *Cancer* 32(5):1186-1201, 1973.
- ¹⁷⁻ Buetow SA.: "Epidemiology of testicular cancer". *Epidemiol. Rev* 17(2): 433-49, 1995.
- ¹⁸⁻ Berthelsen JG, Skakkebaek NE, Sorensen BC, Mogensen P: "Screening for carcinoma in situ of the contralateral testis in patients with germinal testicular cancer". *Br Med J (Clin Res Ed)*. 285:1683-1686, 1982.
- ¹⁹⁻ United Kingdom Testicular Cancer Study Group. "Aethiology of testicular cancer: association with congenital abnormalities, age and puberty, infertility and exercice". *BMJ* 308:1393-99, 1994.
- ²⁰⁻ Swerdlow AJ: "The Epidemiology of testicular cancer". *Eur Urol* 23 (suppl 2):35-38, 1993.
- ²¹⁻ Algaba F., Trias I.: "Patología de los tumores testiculares en el adulto". En: *Tumores germinales del testículo*, Germà JR,. Editor. Ed. Doyma. Cap 2, p- 3, Barcelona 1991.
- ²²⁻ Mostofi FK., Price E.B. Jr. "Tumors of the male genital system". En: *Etlas of tumor pathology, 2^a series, Fasc 8, AFIP*. Washington 1973.
- ²³⁻ Kurman R.J., Scardino P.T., Mc Intire K.R., Waldman T.A., Javadpour N. "Cellular localization of Alpha-fetoprotein and human chorionic gonadotropin in germ cell tumor of the testis using and indirect immunoperoxidase technique. A new approach to classification utilizing tumor markers". *Cancer* 40(5):2136-51, 1977.

- ²⁴⁻ Burke A.P., Mostofi F.K. “Spermatocytic seminoma. A clinico-pathologic study of 79 cases”. J Urol Pathol, 12:75, 1988.
- ²⁵⁻ Niehans G.A., Manivel J.C., Copland G.T., et al. «Inmunohistochemistry of germ cell and trophoblastic neoplasms». Cancer 62(6):1113-23, 1988.
- ²⁶⁻ Matoska J., Ondrus D., Hornak M.: “Metastatic spermatocytic seminoma, a case report with light microscopic, Ultrastructural, and inmunohistochemical findings”. Cancer 62(6):1197-1201, 1988.
- ²⁷⁻ Vugrin D., Chen A., Feigl et al. : «Embryonal carcinoma of the testis». Cancer 61(11):2348-52, 1988.
- ²⁸⁻ Mostofi F.K., Sesterhenn I.A.: “Pathology of germ cell tumors of testis”. Prog Clin Biol Res 203:1-34, 1985.
- ²⁹⁻ Talerman A.: “Endodermal sinus (Yolk Sac) tumor elements in testicular germ cell tumors in adults: Comparison of prospective and retrospective studies”. Cancer 46(5):1213-7, 1980.
- ³⁰⁻ Talerman A., Haije W.G., Baggeman L.: “Histological patterns in germ cell tumors associated with raised serum alpha-fetoprotein (AFP)”. Scan J Inmunol suppl. 8:97-101, 1978.
- ³¹⁻ Ulbright T.M.: “Germ cell neoplasms of the testis”. Am J Surg Pathol 17(11):1075-91, 1993.

- ³²⁻ Ulbright T.M., Roth L.M., Brodhecker C.A.: "Yolk Sac differentiation in germ cell tumors: a morphologic study of 50 cases with emphasis on hepatic, enteric and parietal yolk sac features". Am J Surg Pathol 10(3):151-64, 1986.
- ³³⁻ Kusuda L, Leidich R.B., Das S.: "Mature Teratoma of the testis, metastasizing as mature teratoma". J Urol 135(5):1020-22, 1986.
- ³⁴⁻ Ahmed T., Bosl G.J., Hajdu S.I.: "Teratoma with malignant transformation in germ cell tumors in men". Cancer 56(4):860-3, 1985.
- ³⁵⁻ Skakkebaek NE: "Abnormal morphology of germ cells in two infertile men". Acta Pathol Micro Scand 80(3):374-78, 1972.
- ³⁶⁻ Scully RE: "Intratubular germ cell neoplasia (carcinoma in situ): What it is and what should be done about it". World Urol Update Ser 1:1-19, 1982
- ³⁷⁻ Coffin CM, Ewing S, Dehner LP: "Fecuency of intratubular germ cell neoplasia with invasive testicular germ cell tumors: Histologic and immunocytochemical feature". Arch Pathol Lab Med. 109(6):555-9, 1985.
- ³⁸⁻ Jacobsen GK, Henriksen OB, von der Maase H: "Carcinoma in situ of testicular tissue adjacent to malignant germ cell tumors: A study of 105 cases". Cancer 47(11):2660-2, 1981.
- ³⁹⁻ Muller J, Skakkebaek NE, Nielsen OH, Graem N. "Cryptorchidism and testis cancer. Atypical infantile germ cells followed by carcinoma in situ

- and invasive carcinoma in adulthood". Cancer.* 1984 Aug 15;54(4):629-34.
- ⁴⁰⁻ Rorth M, Rajpert-de Meyts E, Andersson L, Dieckmann KP, Fossa SD, Grigor KM, Hendry WF, Herr, Looijenga LH, Osterhuis JW, Skakkebaek NE. *"Carcinoma in situ in the testis". Scand J Urol Nephrol Suppl.* 2000;(205):166-86.
- ⁴¹⁻ Dieckmann KP, Skakkebaek NE. *"Carcinoma in situ of the testis: review of biological and clinical features". Int J Cancer.* 1999 Dec 10;83(69):815-22.
- ⁴²⁻ Kleinschmidt K, Kemper J, Holstein AF. *"Carcinoma in situ of the testis in the presence of contralateral germ cell tumor". Eur Urol.* 16(1):74-7. 1989;
- ⁴³⁻ Müller J, Skakkebaek NE, Lundsteen C. *"Aneuploidy as a marker for carcinoma in situ of the testis". APMIS;89:67-69, 1981.*
- ⁴⁴⁻ Vos A, Oosterhuis JW, de Jong B, Buist J, Schraffordt Koops H. *"Cytogenetics of carcinoma in situ of the testis". Cancer Genet Cytogenet* ;46(1):75-81, 1990.
- ⁴⁵⁻ Aleksander Giwercman and Niels E. Skakkebaek. *"Carcinoma in situ of the testis". Cap 63, p-663-669 En: Principles and Practice og Genitourinary Oncology. Lippincott-Raven Publishers, Philadelphia.* 1997.

- ⁴⁶⁻ Ulbright Thomas M. Risc.: “Prognostic factors in testicular cancer”. *The Urol Clin North Amer, Uropathology*. Vol 26(3) 611-26. 1999.
- ⁴⁷⁻ Jamieson J.K. and Dobson J.F.: “The lymphatics of the testicle”. *Lancet*, 1: 493, 1910.
- ⁴⁸⁻ Busch F.M. and Sayegh E.S.: “Roentgenographic visualization of human testicular lymphatics: a preliminary report”. *J. Urol.*, 89:106-110, 1963.
- ⁴⁹⁻ Busch F.M. and Sayegh E.S. and Chenault O.W.: “Some uses of lymphangiography in the management of testiculat tumors”. *J. Urol*, 93:490-5, 1965.
- ⁵⁰⁻ Chiappa S., Uslenghi C., Galli G., Ravasi G. And Bonadonna G.: “Lymphangiography and endolymphatic radiotherapy in testicular tumors”. *Brit. J. Rad.*, 39(463): 498-512, 1966.
- ⁵¹⁻ Travel F.R., Osius T.G., Parker J.W., Godtfriend R.B., McGonigle D.J., Jassie M.P., Simmons E.L., Tobenkin M.I. and Schutle J.W.: “Retroperitoneal lymph node dissection”. *J. Urol.*, 89; 241-246, 1963.
- ⁵²⁻ Wahlqvist L., Hulten L. And Resencrantz M.: “Normal lymphatic drainage of the testis studied by funicular lymphangiography”. *Acta Chir. Scand.* 132(4); 454-65, 1966.
- ⁵³⁻ Donohue J.P., Zachary J.M. and Maynard B.R.: “Distribution of nodal metastases in nonseminomatous testis cancer”. *J. Urol.* 128; 315-320. 1982.

- ⁵⁴⁻ Donohue J.P.: "Metastasic pathways of Nonseminomatous Germ Cell Tumors". *Sem Urol.* 2(4):217-29, 1984.
- ⁵⁵⁻ Rai B., Hadju S.I., Withmore WF. "Distribution of retroperitoneal lymph node metastases in the testicular germinal tumors". *Cancer*, 33:340-47, 1974.
- ⁵⁶⁻ Waldmann TA. "Tumour markers in the diagnosis and management of patients with testicular neoplasms. Testicular germ cell neoplasms: recent advances in diagnosis and therapy". *Ann Intern Med*, 90:385-90, 1979.
- ⁵⁷⁻ Germà JR. "Utilidad de los marcadores tumorales en el diagnóstico, pronóstico y seguimiento de los tumores germinales gonadales". Tesis Doctoral, 1985.
- ⁵⁸⁻ Germà Lluch JR., "Uso racional de los marcadores tumorales en los tumores germinales testiculares". *Tumores germinales de testículo*, pag 39-53, Ed. Doyma, Barcelona 1991.
- ⁵⁹⁻ Dean R., Moul J.W.: "New tumoral markers in testis cancer". *Urol Clin Of North America*, 3;397-407. 1998.
- ⁶⁰⁻ Atkin N.B., Baker M.C.: "Specific chromosome change, i(12p) in testicular tumors ?". *Lancet* 2(8311):1349, 1982.
- ⁶¹⁻ Bosl G.J, Dimitrovsky E, Reuter V.E, et al.: "Isochromosome of short arm of chromosome 12: Clinically useful marker for male germ cell tumors". *J Natl Cancer Inst* 81(24):1874-8, 1989.

- ⁶²⁻ Germà Lluch J.R., Arcusa A., casamitjana R.: “False elevation of human chorionic gonadotrophin associated to iatrogenic hypogonadion in gonadal germ cell tumours”. *Cancer*, 60:2, 489-93. 1987.
- ⁶³⁻ Javadpour N., Soares T.: “False positive and false negative alpha-fetoprotein and human chorionic gonadotrophin assays in testicular cancer”. *Cancer* 48:2.279-81, 1981
- ⁶⁴⁻ Grem J.L., Trump D.L., “Reversible increase in serum A-fetoprotein content associated with hepatic dysfunction during chemotherapy for seminoma”. *J Clin Oncol*, 4:41-45, 1986.
- ⁶⁵⁻ Coakley F.V. et al.: “Estudio de imagen y tratamiento de los tumores testiculares atípicos”. *Urol Clin Of North America*, 3;409-424. 1998.
- ⁶⁶⁻ Hricak H, hamm B, Kim B: “Imaging of the scrotum”: Textbook and atlas. New Cork, Raven Press, pg 49-93, 1995.
- ⁶⁷⁻ Thurnher S, Hricak H, Carroll PR, Pobiel RS, Filly RA. “Imaging the testis. Comparison between MR imaging and US”. *Radiology* 1988; 167:631-36.
- ⁶⁸⁻ Mattrey RF. “Magnetic Resonante imaging of the scrotum”. *Semin Ultrasound CT MR* 1991; 12: 95-108
- ⁶⁹⁻ Rholl KS, Lee JKT, Ling D, Heiken JP, Glazer HS. “MR imaging of the scrotum with a high resolution surface coil”. *Radiology* 1987; 163:99-103

- ⁷⁰⁻ Johnson HO, Mattrey RF, Phillipson J. "Differentiation of seminomatous from nonseminomatous testicular tumors by MRI". Am J Roetgenol 154: 539-43, 1990.
- ⁷¹⁻ See WA, Hoxie L. "Chest staging in testis cancer patients:imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results". J urol 150:874-878, 1993.
- ⁷²⁻ Leibovitch I, Foster RS, Kopecky KK, Donohue JP. "Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes". J. Urol 154: 1759-63, 1995.
- ⁷³⁻ Ellis JH, Blies JR, Kopecky KK, Klatte EC, Rowland RG, Donohue JP. "Comparison of NMR and CT imaging in the evaluation of metastatic retroperitoneal lymphadenopathy from testicular carcinoma". J Comput Assist Tomogr 8:709-719, 1984.
- ⁷⁴⁻ Cremerius U, Wildberger JE, Borchers H, Zimny M, Jakse G, Gunther RW, Buell U. "Does PET using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer ? results of a study in 50 patients". Urology 54(5):900-904, 1999.
- ⁷⁵⁻ De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K, Dohmen BM. Dittrich C.: "Predictive impact of 18-fluoro-2-deoxyglucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma". J Clin Oncol 19: 3740-44, 2001.

- ⁷⁶⁻ Zagars GK. “Management of stage I seminoma: radiotherapy”. In: *Testicular cancer: Investigation and Management*. Horwich A (ed.): Chapman and Hall Medical: London, p-99, 1999.
- ⁷⁷⁻ Kleep O, Flodgren P, Maartman-Moe H, Lindholm CE, Unsgaard B, Teigum H, Fossa SD, Paus E.: “Early clinical stages (CS1, CS1 Mk+ and CS2A) of non-seminomatous testis cancer”. *Ann Oncol* 1:281-288, 1990.
- ⁷⁸⁻ International Germ Cell Cancer Collaborative Group. *International Germ Cell Consensos Classification: “A prognostic factor based staging system for metastatic germ cell cancers”*. *J Clin Oncol* 15(2):594-603, 1997.
- ⁷⁹⁻ Sternberg CN. “The management of stage I testis cancer”. *Urol Clin North Am* 25: 435-449, 1998
- ⁸⁰⁻ Van Leeuwen FE, Stiggelbout AM, Van der Belt-Dusebout AW, Noyon R, Eliel MR, Van Kerhoff EH, Delemarre JF, Somers R.: “Second cancer risk following testicular cancer: a follow-up stdy of 1909 patients”. *J Clin Oncol* 11: 415-424, 1993.
- ⁸¹⁻ Warde P, Jewett MAS.: “Surveillance for stage I testicular seminoma. Is it a good option?” *Urol Clin North Am* 25: 425-433, 1998..
- ⁸²⁻ Sharda N, Kinsella T, Ritter M.: “Adjuvant radiation versus observation: a cost análisis of alternate management schemes in early-stage testicular seminoma”. *J Clin Oncol*; 14: 2933-2939, 1996.

- ⁸³⁻ Warde P, Von der Maase H, Horwich A. “Prognostic factors for relapse in stage I seminoma managed by surveillance”. Proc Am Soc Clin Oncol 17: 312-315, 1998.
- ⁸⁴⁻ Hilton S, Herr HW, Teitcher JB, et al.: “CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer”. Am J Roetgenol 169:521-25, 1997.
- ⁸⁵⁻ Cullen MH, Stenning Sp, Parkinson MC et al.: “Short course adjuvant chemotherapy in high risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report”. J Clin Oncol 14:1106-1111, 1996.
- ⁸⁶⁻ Böhlen D, Borner M, Sonntag RW et al.: “Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors”. J Urol 161: 1148-1151, 1999.
- ⁸⁷⁻ De Wit R, Louwerens M, de Mulder PH, Verweij J, Rodenhuis S, Schornagel J.: “Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of taxol-BEP”. Int J Cancer 83:831-833, 1999.
- ⁸⁸⁻ Reinhorn LH, Rajabani D, KIndlen H.: “A Phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory advanced germ cell tumors”. Proc. ASCO 18:207 A (abst. 796), 1999.
- ⁸⁹⁻ Bhatia S, Abonour R, Porcu P, Seshadri R, Nichols CR, Cornetta K, Einhorn LH.: “High-dose chemotherapy as initial salvage chemotherapy

- in patients with relapsed testicular cancer". J Clin Oncol 18:3346-3351, 2000.*
- ⁹⁰⁻ Pamenter B, De Bono JS, Brown IL, Nandini M, Kaye SB, Russell JM, Yates AJ, Kirk D.: "Bilateral testicular cancer: a preventable problem ? Experience from large cancer center". *BJU Int.* Jul; 92(1):43-46, 2003.
- ⁹¹⁻ Chilpe S, Flechon A, Droz J.P.: "Cancer of the testis: role of radiotherapy in 2003". *Cancer Radiother.* Nov; 7 Suppl 1:70s-77s. Review. 2003.
- ⁹²⁻ Algaba y cols.: "Protocolos diagnósticos y pronósticos en uropatología". P-60, Madrid junio-2001
- ⁹³⁻ Donohue J: "Retroperitoneal lymphadenectomy: The anterior approach including bilateral suprarenal hilar dissection". *Urol Clin North Am* 4(3):509-21, 1977.
- ⁹⁴⁻ Einhorn L, Donohue J: "Improved chemotherapy in disseminated testicular cancer". *J Urol* 117(1):65-9, 1977.
- ⁹⁵⁻ Donohue J, Rowland R, Bihrl R: "Transabdominal retroperitoneal lymph node dissection in diagnosis and management of genitourinary cancer". In Skinner DG, Lieskowsky G (eds): *Genitourinary Cancer*. Philadelphia, WB Saunders, , p 80, 1988.
- ⁹⁶⁻ Fossa SD, Ous S, Stenwig AE, Lien HH, Aass N, Kaalhus O.: "Distribution of retroperitoneal lymph node metastases in patients with non seminomatous testicular cancer in clinical stage 1". *Eur Urol* 107-112, 1990.

- ⁹⁷⁻ Donohue JP, Foster RS, Rowland RG, Birhle R, Geier G.: "Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation". *J Urol* 144:287-292, 1990.
- ⁹⁸⁻ Jewett MA, Kang YS, Golberg SD, Sturgeon JF, Thomas GM, Alison RE et al.: "Retroperitoneal lymphadenectomy for testicular tumor with nerve-sparing for ejaculation". *J Urol* 139:1220-24, 1988.
- ⁹⁹⁻ Herr HW, Sheinfeld J, Puc HS, Heelan R, Bajorin DF, Mencel P, Bosl GJ, Motzer RJ: "Surgery for a post-chemotherapy residual mass in seminoma". *J. Urol.* 860-862, 1997.
- ¹⁰⁰⁻ Schutz SM, Einhorn LH, Conces DJ Jr, Williams SD, Loehrer PJ.: "Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience". *J. Clin. Oncol.*, 1497-1503, 1989.
- ¹⁰¹⁻ Debono DJ, Heilman DK, Einhorn LH, Donohue JP.: "Decisión análisis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors". *J Clin Oncol* 1455-1464, 1997.
- ¹⁰²⁻ Albers P, Ganz A, Hanning E, Miersch WD, Müller SC.: "Salvage surgery of chemotherapy germ cell tumors with elevated tumor markers". *J Urol* 164:: 381-384, 2000.
- ¹⁰³⁻ Eastham JA, Wilson TG, Russell C, Ahlering TE, Skinner DG.: "Surgical resection in patients with nonseminomatous germ cell tumor who fail to

normalize serum tumor markers after chemotherapy". Urology 43(1):74-80, 1994.

- ¹⁰⁴⁻ WeinKnecht S, Bussar-Maatz R, Albers P, Weissbach L.: "Is the resection of residual tumors in patients with germ cell tumors and positive markers justified?" Urologe A, , 68-72. 1997.
- ¹⁰⁵⁻ Wood DP, Herr HW, Motzer RJ, Reuter V, Sogani PC, Morse MJ, Bosl GJ.: Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer 70(9) 2354-7, 1992.
- ¹⁰⁶⁻ Ges ME, Nijboer AP, Hoekstra HJ, Sleijfer DT, Molenaar WM, Plukker JT, Droste JH, Schraffordt Koops H.: "Complications of the post-chemotherapy resection of retroperitoneal residual tumour mass in patients with non-seminomatous testicular germ cell tumours". Br J. Urol 263-268, 1997.
- ¹⁰⁷⁻ Moul JW, Robertson JE, George SL, paulson DF, Walther PJ.: "Complications of therapy for testicular cancer". J Urol 1491-1496, 1989.
- ¹⁰⁸⁻ Skinner DG, Melamud A, Lieskovsky G.: "Complications of thoracoabdominal retroperitoneal lymph node dissection". J. Urol 1107-1110, 1992.
- ¹⁰⁹⁻ Logothetis CJ, Samuels ML, Trinidad A y Cols.: "The Growing Teratoma Síndrome". Cancer, 50(8):1629-35, 1982.

- ¹¹⁰⁻ Jeffery GM, Teaker JM, Lee AHS y cols.: "The growing Teratoma Síndrome". Br J Urol 67(2):195-202, 1991.
- ¹¹¹⁻ Ponce de León J, Villavicencio H.: Síndrome del "Growing teratoma" Arch Esp Urol., 53, 6(547-552), 2000.
- ¹¹²⁻ Villavicencio H, Solé F.: "Cirugía retroperitoneal en los tumores germinales de testículo". En: Germà JR y Cols.: Tumors germinales de testículo, Monografías clínicas en oncología. Madrid Ed. Doyma S.A. p 65-75, 1991.
- ¹¹³⁻ Urruchi P, cavero O, Jiménez JA.: "Síndrome del teratoma en crecimiento". Actas Urol Esp : 205-8, 1992.
- ¹¹⁴⁻ Tonkin KS, Rustin GJS, Wignall B y cols.: "Successful treatment of patients in whom germ cell tumour massesenlarged on chemotherapy while their serum tumour markers decreased". Eur J cancer 25(12): 1739-43, 1989.
- ¹¹⁵⁻ Sagalowsky A.I., Ewalt D.H., Molberg K., Peters P.C.: "Predictors of residual mass histology alter chemotherapy for advanced testis cancer". Urology 35,537-542, 1990.
- ¹¹⁶⁻ Donohue JP y cols. "Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer". J Urol 137, 1176-1179, 1987.

- ¹¹⁷⁻ Stomper PC, Jochelson MS, Garnick M, Richie J.: "Residual abdominal masses after chemotherapy for nonseminomatous testicular cancer: correlation of Ct and histology" AJR 145:743-46, 1985.
- ¹¹⁸⁻ Matsuyama H, Hayashida S, Yamamoto N, kamiryo Y y cols: "Predictive factors for the histologic nature of residual tumor mass alter chemotherapy in patients with advanced testicular cancer". Urology Jan 13: 392-399, 1994.
- ¹¹⁹⁻ Steyerberg EW, Keizer HJ, Stoter G, habbema JDF.: "Predictors of residual mass histology following chemotherapy for metastasic non-seminomatous testicular cancer: a quantitative overview of 996 resections" Eur J Can, 30; 9:1231-1239, 1994.
- ¹²⁰⁻ Steyerberg EW, Keizer HJ, Fossa SD, Toner H, Koops S, Mulders PFA, Messemer JE, Ney K, Donohue JP, Bajorin G, Stoter G, Bosl GJ, Habbema JDF.: "Prediction of residual retroperitoneal mass histology after chemotherapy for metastasic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups". J Clin Oncol, 13(5): 1177-1187, 1995.
- ¹²¹⁻ Steyerberg EW, Keizer HJ, Fossa SD, Sljifer DT, Bajorin DF, Donohue JP, Habbema JDF for the ReHiT study group.: "Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria". B J Can 74, 1492-1498, 1996.
- ¹²²⁻ Steyerberg EW, Keizer HJ, habbema JDF.: "Prediction models for the histology of residual masses after chemotherapy for metastasic testicular cancer". Int J Cancer, 10, 83(6):856-859, 1999.

- ¹²³⁻ Vergouwe Y, Steyerberg EW, Foster R, Habbema JDF, Donohue J.: “Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer”. *J Urol* 165, 84-88, 2001.
- ¹²⁴⁻ Vergouwe Y, Steyerberg EW, de Wit R, Roberts JT, Keizer HJ, Collette L, Stenning SP, Habbema JDF.: “External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients”. *B J Cancer* 88, 843-847, 2003.
- ¹²⁵⁻ Albers P, Weinknecht S, Krege S, Kriesch S, Hartmann M, Heidenreich A, et al.: “Prediction of necrosis after chemotherapy of advanced germ cell tumors- Results of a prospective multicenter trial of the GTCSG”. *J Urol Suppl*;167:172-80, 2002.
- ¹²⁶⁻ Germà-Lluch JR, Garcia del Muro et al.: “Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (CG)”. *Eur Urol* 42, 553-563, 2002.
- ¹²⁷⁻ Milton S, Herr HW, Teicher JB, et al.: “CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria”. *AJR AM J Roentgenol* 169:521-5, 1997.
- ¹²⁸⁻ Flechon A, Bompas E, Biron P, et al: “Management of post-chemotherapy residual masses in advanced seminoma”. *J Urol* 168:1975-79, 2002.

- ¹²⁹⁻ Motzer R, Bosl G, Heelan R, et al.: "Residual mass: An indication for further therapy in patients with advanced seminoma following systemic chemotherapy". J Clin Oncol 5(7):1064-70, 1987.
- ¹³⁰⁻ Herr HW, Sheinfeld J, Puc HS, Heelan R, bajorin DF, Mencel P, Bosl GJ, Motzer RJ.: "Surgery for a post-chemotherapy residual mass in seminoma" J Urol 157(3):860-2, 1997.
- ¹³¹⁻ Ravi R, Ong J, Oliver RT, Badenoch DF, Fowler CG, Hendry WF.: "The management of residual masses after chomotherapy in metastatic seminoma" BJU Int. 83(6):649-53, 1999.
- ¹³²⁻ Mosharafa AA, Foster RS, Leibovich BC, et al.: "Is the postchemotherapy resection of seminomatous elements associated with higher acute morbidity?". J Urol 167:172, 2002.
- ¹³³⁻ Foster R, Baniel J, Leibovitch I et al.: "Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma low stage nonseminomatous testis cancer". J Urol 155(6):1943-5, 1996.
- ¹³⁴⁻ Germà et al. "Multicenter study evaluating a dual policy of postorchectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma". Ann Oncol jun;14(6):867-72, 2003.

- ¹³⁵⁻ Vergouwe Y et al. "Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review". J Clin Oncol. Nov 15;21(22):4092-9, 2003.
- ¹³⁶⁻ Nicolai et al. "A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only". J Urol Jan;171(1):172-6, 2004.
- ¹³⁷⁻ Toner GC, Panicek DM, Heelan RT, et al.: "Adjuvantive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendation for patients selection". J Clin Oncol 8, 1683-94, 1990.
- ¹³⁸⁻ Tait D, Peckam MJ, Hendry WF, Goldstraw P. "Post-chemotherapy surgery in advanced non-seminomatous germ-cell tumours: the significance of histology with particular reference to differentiated (mature) teratoma". Br J cancer 54,2716-2721, 1984.
- ¹³⁹⁻ Jansen RLH, Sylvester R, Sleyfer DT, et al.: « Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery ». Eur J cancer 27,695-698. 1991.
- ¹⁴⁰⁻ Gelderman WAH, Scraffordt H, Sleijfer DTh, et al.: "Results of adjuvant surgery in patients with stage III and IV nonseminomatous testicular tumors after cisplatin-vinblastine-bleomycin chemotherapy". J Surg Oncol 38,227-232, 1988.

- ¹⁴¹⁻ Husband JE, Hawkes DJ, Peckham MJI. "CT estimation of mean attenuation values and volume in testicular tumors: a comparison with surgical and histologic findings". Radiology 144:553-558, 1982.
- ¹⁴²⁻ Hendry WF, Barrett A, McElwain TJ, Wallace DM, Peckham MJ.: "The role of surgery in the combined management of metastases in testicular carcinoma". J Comput Assist Tomogr 7:682-687, 1983.
- ¹⁴³⁻ Soo C, Bernardino ME, Chiang VP, Ordoñez N.: "Pitfalls of CT findings in post-therapy testicular carcinoma". J Comput Assist Tomogr 5:39-41, 1981.
- ¹⁴⁴⁻ Zingas AP, Jain AB, Loredo RD, Kling GAI.: "The spectrum of computed tomographic appearance of metastatic masses from testicular neoplasms". J Comput Assist Tomogr 8:53-60, 1984.
- ¹⁴⁵⁻ Scatarige JC, Fishman EK, Kuhajda FP, Taylor GA, Siegelman SS.: "Low attenuation nodal metastases in testicular carcinoma". J Comput Assist Tomogr 7:682-87, 1983.
- ¹⁴⁶⁻ Herr HW, Sheinfeld J, Puc HS, Heelan R, Bajorin DF, Mencel P, Bosl GJ, Motzer RJ: et al. "Residual mass after chemotherapy for seminoma: Changing concepts of management". J Urol 137(6): 1234-5, 1987.
- ¹⁴⁷⁻ Fossa SD, Qvist H, Stenwig A et al.: "Is post chemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?" J Clin Oncol 10:569-573, 1992.

- ¹⁴⁸⁻ Albers P, Melchior D, Müller S.: "Surgery in metastatic testicular cancer". Eur Urol 44(2): 233-244, 2003.
- ¹⁴⁹⁻ Fizazi K, Tjulandin S, Salvioni R, Germà-Lluch JR, Bouzy J, ragan D, et al.: "Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy – results from an internatinal study group". J Clin Oncol 19: 2647-57, 2001.

Bibliografia
